Presentation and Management of Gastrointestinal Stromal Tumour (GIST ) Among Sudanese Patients from April 2015 to April 2019
DOI:
https://doi.org/10.47363/JGHR/2022(3)145Keywords:
Gastrointestinal Stromal Tumour, Abdominal Features, Duodeno-PancreaticAbstract
Background: Gastrointestinal stromal tumour is one of the common alimentary tract tumour and it have different anatomical site of occurrence; there are international data that are common to occur in the stomach but no local data about the common site in Sudanese patients and the presentation.
Objective: To asses presentation and management of gastrointestinal stromal tumour among Sudanese patients.
Methods: Prospective, retrospective cross-sectional study, hospital based. The study was conducted to Ibnsina hospital (gastroenterology centre) in Khartoum state during the period from April 2015 to April 2019. The study sample was determines as total coverage of the study period. The eligible cases fulfilled the inclusion criteria was 62 patients. Data was collected using a constructed structure questionnaire.
Results: In this study the mean age was 53.3±14.3 years. Male to female ratio was 2.4:1 Regarding characteristics of abdominal mass, the study revealed that all masses were epigastric in site. On the other hand our study showed that the mean size was 18.8±19.7 (cm). In patients with GIST the shape of abdominal mass reported in 88.5 %( n=23), irregular 11.5 %( n=3), regular surface 92.3 %( n=24), irregular 7.7 %(n=2). Firm 96.2 %( n=25) and hard 3.8 %( n=1). Motility 80.8 %( n=21) and immobility 19.2 %( n=2). Attached 11.5 %( n=3) not attached 88.5 %( n=23). The most common options of surgery were wedge resection 51.6 %( n=32), proximal gastrectomy 11.3 %( n=7), distal gastrectomy. The outcome of patients at postoperative 6 months FU was improvement 77.4 %( n=48), death 14.5 %( n=9) and recurrence 8.1 %( n=5).
Conclusion: Imatinib showed good response when used as neoadjuvent therapy to down size the tumour and also as adjuvant to prevent recurrent.
